Discovery and development of antibody therapies for COVID-19

Neutralizing antibodies (nAbs) against SARS-CoV-2 represent a promising option for treating COVID-19. Screening a large and diverse antibody phage library has allowed for the rapid discovery of anti-SARS-CoV-2 nAbs.

In this expert webinar, find out how high-throughput epitope binning and mapping using using label-free biolayer interferometry (BLI) detection and advanced flow cytometry systems has enabled the development of an antibody cocktail that can reduce the risk of drug resistance.

Key learning objectives:

• Describe how neutralizing antibodies can be used as a drug modality for the treatment of COVID-19
• Identify components of SARS-CoV-2 relevant to resistance against antibody therapy
• Evaluate strategies for the discovery and development of neutralizing antibodies for research applications

Who should attend?

• Biopharma and biotech representatives
• Novel vaccine and treatment developers
• Researchers interested in DNA/RNA